MRUS - Merus N.V.
NASDAQ
->
Healthcare
->
Biotechnology
Utrecht,
Netherlands
Type: Equity
MRUS price evolution
MRUS
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | ||||
| Short term investments | ||||
| Net receivables | $3.88 | $3.9 | $60.42 | $3.98 |
| Inventory | ||||
| Total current assets | $666.28 | $806.55 | $410.26 | $368.81 |
| Long term investments | ||||
| Property, plant & equipment | $22.46 | $22.38 | $22.1 | $23.5 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $844.68 | $892.23 | $498.08 | $455.49 |
| Current liabilities | ||||
| Accounts payable | $6.18 | $4.39 | $7.49 | $4.6 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $80.08 | $80.86 | $78.49 | $69.09 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $141.41 | $145.46 | $148.63 | $99.15 |
| Shareholders' equity | ||||
| Retained earnings | -$937.46 | -$837.56 | -$787.52 | -$753.06 |
| Other shareholder equity | -$7.12 | -$38.9 | -$29.92 | -$22.53 |
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $241.44 | $163.08 | ||
| Short term investments | $168.99 | $44.67 | ||
| Net receivables | $3.98 | $4.7 | $6.31 | $1.75 |
| Inventory | ||||
| Total current assets | $368.81 | $306.44 | $424.18 | $217.99 |
| Long term investments | $20.3 | |||
| Property, plant & equipment | $23.5 | $24.84 | $7.28 | $8.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $13.22 | |||
| Total investments | ||||
| Total assets | $455.49 | $376.54 | $456.6 | $231.22 |
| Current liabilities | ||||
| Accounts payable | $4.6 | $9.83 | $13.24 | $3.13 |
| Deferred revenue | $20.18 | |||
| Short long term debt | ||||
| Total current liabilities | $69.09 | $78.93 | $71.9 | $46.75 |
| Long term debt | ||||
| Total noncurrent liabilities | $82.21 | |||
| Total debt | ||||
| Total liabilities | $99.15 | $129.49 | $140.4 | $128.95 |
| Shareholders' equity | ||||
| Retained earnings | -$753.06 | -$598.12 | -$466.93 | -$400.11 |
| Other shareholder equity | -$22.53 | -$30.45 | -$9.22 | $9.07 |
| Total shareholder equity | $316.2 | $102.26 | ||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.77 | $7.33 | $7.89 | $8.94 |
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $84 | $71.71 | $54.7 | $56.48 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $2.98 | $2.32 | $1.1 | $1.04 |
| Interest expense | -$24.7 | $16.65 | $13.45 | -$11.57 |
| Net income | ||||
| Net income | -$99.91 | -$50.04 | -$34.46 | -$60.15 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 30 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $43.95 | $41.59 | $29.94 | |
| Cost of revenue | $70.04 | |||
| Gross Profit | -$40.1 | |||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $35.78 | |||
| Total operating expenses | $200.49 | $201.62 | $105.82 | |
| Operating income | -$75.88 | |||
| Income from continuing operations | ||||
| EBIT | -$75.88 | |||
| Income tax expense | $3.19 | $0.96 | $0.5 | |
| Interest expense | $4.8 | $28.74 | ||
| Net income | ||||
| Net income | -$154.94 | -$131.19 | -$85.51 | |
| Income (for common shares) | -$85.51 | |||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$142.52 | -$8.85 | -$12.08 | -$27.02 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $485.94 | $475.05 | $30.16 | $230.09 |
| Effect of exchange rate | $4.51 | -$2.24 | $0.22 | -$4.29 |
| Change in cash and equivalents | $228.76 | $425.21 | -$26.09 | $56.58 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 30 Dec 2021 | 30 Dec 2020 |
|---|---|---|---|---|
| Net income | -$66.82 | -$85.51 | ||
| Operating activities | ||||
| Depreciation | $1.44 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$79.9 | |||
| Investing activities | ||||
| Capital expenditures | -$1.29 | |||
| Investments | -$0.2 | |||
| Total cash flows from investing | -$27.02 | $2.8 | -$1.49 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $230.09 | $58.74 | $39.52 | |
| Effect of exchange rate | -$4.28 | -$4.95 | $7.34 | |
| Change in cash and equivalents | $56.58 | -$93.31 | -$34.53 | |
News
Fundamentals
| Market cap | $6.50B |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 68.43M |
| Revenue | $35.93M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$244.56M |
| Revenue Q/Q | 6.70% |
| Revenue Y/Y | -21.33% |
| P/E ratio | -26.59 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 180.99 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$3.57 |
|---|---|
| ROA | -36.36% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 8.32 |
| Quick ratio | N/A |